{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:24:38Z","timestamp":1785432278046,"version":"3.56.0"},"reference-count":50,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Autoimmune hemolytic anemia (AIHA) is most often idiopathic. However, in recent years, AIHA has been noted with increased incidence in patients receiving purine nucleoside analogues for hematologic malignancies; it has also been described as a complication of blood transfusion in patients who have also had alloimmunization. As the technology of hematopoietic stem cell transplantation has become more widespread, immune hemolysis in the recipients of ABO-mismatched products has become better recognized. The syndrome is caused by passenger lymphocytes transferred from the donor, and although transient, can be quite severe. A similar syndrome has been observed in recipients of solid organ transplants when there is ABO-incompatibility between donor and recipient.<\/jats:p>\n               <jats:p>Venous thromboembolism is a little-recognized, though likely common, complication of autoimmune hemolytic anemia (AIHA), and may in some instances be related to coexistent antiphospholipid antibodies. While AIHA is a well-documented complication of malignant lymphoproliferative disorders, lymphoproliferative disorders may also paradoxically appear as a consequence of AIHA.<\/jats:p>\n               <jats:p>A number of newer options are available for treatment of AIHA in patients refractory to corticosteroids and splenectomy. Newer immunosuppressives such as mycophenolate may have a role in such cases. Considerable experience has been accumulating in the last few years with monoclonal antibody therapy, specifically rituximab, in difficult AIHA cases; it appears to be a safe and effective option.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.13","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T18:14:02Z","timestamp":1164219242000},"page":"13-18","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Immune Hemolytic Anemia\u2014Selected Topics"],"prefix":"10.1182","volume":"2006","author":[{"given":"Philip C.","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702200505300_R1","doi-asserted-by":"crossref","unstructured":"Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol. 1995;91:341\u2013344.","DOI":"10.1111\/j.1365-2141.1995.tb05300.x"},{"key":"2019111702200505300_R2","doi-asserted-by":"crossref","unstructured":"Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol. 1998;16:1885\u20131889.","DOI":"10.1200\/JCO.1998.16.5.1885"},{"key":"2019111702200505300_R3","doi-asserted-by":"crossref","unstructured":"Fleischman RA, Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am J Hematol. 1995;48:293.","DOI":"10.1002\/ajh.2830480423"},{"key":"2019111702200505300_R4","doi-asserted-by":"crossref","unstructured":"Aslan DL, Peterson BA, Long-Tsai M, Eastlund T. Early-onset autoimmune hemolytic anemia after cladribine therapy for Waldenstrom\u2019s macroglobulinemia. Transfusion. 2006;46:90\u201394.","DOI":"10.1111\/j.1537-2995.2006.00678.x"},{"key":"2019111702200505300_R5","doi-asserted-by":"crossref","unstructured":"Byrd JC, Hertler AA, Weiss RB, Freiman J, Kweder SL, Diehl LF. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol. 1995;6:300\u2013301.","DOI":"10.1093\/oxfordjournals.annonc.a059162"},{"key":"2019111702200505300_R6","doi-asserted-by":"crossref","unstructured":"Paydas S. Fludarabine-induced hemolytic anemia: successful treatment by rituximab. Hematol J. 2004;5:81\u201383.","DOI":"10.1038\/sj.thj.6200339"},{"key":"2019111702200505300_R7","doi-asserted-by":"crossref","unstructured":"Young PP, Uzieblo A, Trulock E, Lublin DM, Goodnough LT. Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion. 2004;44:67\u201372.","DOI":"10.1046\/j.0041-1132.2003.00589.x"},{"key":"2019111702200505300_R8","doi-asserted-by":"crossref","unstructured":"Garratty G. Autoantibodies induced by blood transfusion. Transfusion. 2004;44:5\u20139.","DOI":"10.1111\/j.0041-1132.2004.00658.x"},{"key":"2019111702200505300_R9","doi-asserted-by":"crossref","unstructured":"Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;42:37\u201343.","DOI":"10.1046\/j.1537-2995.2002.00007.x"},{"key":"2019111702200505300_R10","doi-asserted-by":"crossref","unstructured":"Castellino SM, Combs MR, Zimmerman SA, Issitt PD, Ware RE. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol. 1999;104:189\u2013194.","DOI":"10.1046\/j.1365-2141.1999.01127.x"},{"key":"2019111702200505300_R11","doi-asserted-by":"crossref","unstructured":"Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood. 2000;96:3369\u20133373.","DOI":"10.1182\/blood.V96.10.3369"},{"key":"2019111702200505300_R12","doi-asserted-by":"crossref","unstructured":"Bolan CD, Childs RW, Procter JL, Barrett AJ, Leitman SF. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol. 2001;112:787\u2013795.","DOI":"10.1046\/j.1365-2141.2001.02587.x"},{"key":"2019111702200505300_R13","doi-asserted-by":"crossref","unstructured":"Worel N, Greinix HT, Keil F, et al. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion. 2002;42:1293\u20131301.","DOI":"10.1046\/j.1537-2995.2002.00209.x"},{"key":"2019111702200505300_R14","doi-asserted-by":"crossref","unstructured":"Petz LD. Immune hemolysis associated with transplantation. Semin Hematol. 2005;42:145\u2013155.","DOI":"10.1053\/j.seminhematol.2005.05.017"},{"key":"2019111702200505300_R15","doi-asserted-by":"crossref","unstructured":"Bensinger WI, Buckner CD, Thomas ED, Clift RA. ABO-incompatible marrow transplants. Transplantation. 1982;33:427\u2013429.","DOI":"10.1097\/00007890-198204000-00017"},{"key":"2019111702200505300_R16","doi-asserted-by":"crossref","unstructured":"Gajewski JL, Petz LD, Calhoun L, et al. Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate. Blood. 1992;79:3076\u20133085.","DOI":"10.1182\/blood.V79.11.3076.3076"},{"key":"2019111702200505300_R17","doi-asserted-by":"crossref","unstructured":"Tiplady CW, Fitzgerald JM, Jackson GH, Conn JS, Proctor SJ. Massive haemolysis in a group A recipient of a group O peripheral blood stem cell allogeneic transplant. Transfus Med. 2001;11:455\u2013458.","DOI":"10.1046\/j.1365-3148.2001.00334.x"},{"key":"2019111702200505300_R18","doi-asserted-by":"crossref","unstructured":"O\u2019Brien TA, Eastlund T, Peters C, et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol. 2004;127:67\u201375.","DOI":"10.1111\/j.1365-2141.2004.05138.x"},{"key":"2019111702200505300_R19","unstructured":"Drobyski WR, Potluri J, Sauer D, Gottschall JL. Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;17:1093\u20131099."},{"key":"2019111702200505300_R20","doi-asserted-by":"crossref","unstructured":"Chen FE, Owen I, Savage D, et al. Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant. 1997;19:491\u2013495.","DOI":"10.1038\/sj.bmt.1700677"},{"key":"2019111702200505300_R21","unstructured":"Azuma E, Nishihara H, Hanada M, et al. Recurrent cold hemagglutinin disease following allogeneic bone marrow transplantation successfully treated with plasmapheresis, corticosteroid and cyclophosphamide. Bone Marrow Transplant. 1996;18:243\u2013246."},{"key":"2019111702200505300_R22","doi-asserted-by":"crossref","unstructured":"Dovat S, Roberts RL, Wakim M, Stiehm ER, Feig SA. Immune thrombocytopenia after umbilical cord progenitor cell transplant: response to vincristine. Bone Marrow Transplant. 1999;24:321\u2013323.","DOI":"10.1038\/sj.bmt.1701888"},{"key":"2019111702200505300_R23","doi-asserted-by":"crossref","unstructured":"Mullen CA, Thompson JN, Richard LA, Chan KW. Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia. Bone Marrow Transplant. 2000;25:1093\u20131097.","DOI":"10.1038\/sj.bmt.1702397"},{"key":"2019111702200505300_R24","doi-asserted-by":"crossref","unstructured":"Sevilla J, Gonzalez-Vicent M, Madero L, Diaz MA. Acute autoimmune hemolytic anemia following unrelated cord blood transplantation as an early manifestation of chronic graft-versus-host disease. Bone Marrow Transplant. 2001;28:89\u201392.","DOI":"10.1038\/sj.bmt.1703087"},{"key":"2019111702200505300_R25","doi-asserted-by":"crossref","unstructured":"Urban C, Benesch M, Sovinz P, Schwinger W, Lackner H. Fatal Evans\u2019 syndrome after matched unrelated donor transplantation for hyper-IgM syndrome. Eur J Haematol. 2004;72:444\u2013447.","DOI":"10.1111\/j.1600-0609.2004.00256.x"},{"key":"2019111702200505300_R26","doi-asserted-by":"crossref","unstructured":"Corti P, Bonanomi S, Vallinoto C, et al. Rituximab for immune hemolytic anemia following T- and B-Cell-depleted hematopoietic stem cell transplantation. Acta Haematol. 2003;109:43\u201345.","DOI":"10.1159\/000067271"},{"key":"2019111702200505300_R27","doi-asserted-by":"crossref","unstructured":"Ship A, May W, Lucas K. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation. Bone Marrow Transplant. 2002;29:365\u2013366.","DOI":"10.1038\/sj.bmt.1703371"},{"key":"2019111702200505300_R28","doi-asserted-by":"crossref","unstructured":"Ramsey G. Red cell antibodies arising from solid organ transplants. Transfusion. 1991;31:76\u201386.","DOI":"10.1046\/j.1537-2995.1991.31191096190.x"},{"key":"2019111702200505300_R29","doi-asserted-by":"crossref","unstructured":"Salerno CT, Burdine J, Perry EH, Kshettry VR, Hertz MI, Bolman RM, 3rd. Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation. Transplantation. 1998;65:261\u2013264.","DOI":"10.1097\/00007890-199801270-00021"},{"key":"2019111702200505300_R30","doi-asserted-by":"crossref","unstructured":"Triulzi DJ, Shirey RS, Ness PM, Klein AS. Immunohematologic complications of ABO-unmatched liver transplants. Transfusion. 1992;32:829\u2013833.","DOI":"10.1046\/j.1537-2995.1992.32993110754.x"},{"key":"2019111702200505300_R31","doi-asserted-by":"crossref","unstructured":"Allgood JW, Chaplin H, Jr. Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965. Am J Med. 1967;43:254\u2013273.","DOI":"10.1016\/0002-9343(67)90168-4"},{"key":"2019111702200505300_R32","doi-asserted-by":"crossref","unstructured":"Pullarkat V, Ngo M, Iqbal S, Espina B, Liebman HA. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol. 2002;118:1166\u20131169.","DOI":"10.1046\/j.1365-2141.2002.03729.x"},{"key":"2019111702200505300_R33","doi-asserted-by":"crossref","unstructured":"Kokori SI, Ioannidis JP, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med. 2000;108:198\u2013204.","DOI":"10.1016\/S0002-9343(99)00413-1"},{"key":"2019111702200505300_R34","doi-asserted-by":"crossref","unstructured":"Conley CL, Savarese DM. Biologic false-positive serologic tests for syphilis and other serologic abnormalities in autoimmune hemolytic anemia and thrombocytopenic purpura. Medicine (Baltimore). 1989;68:67\u201384.","DOI":"10.1097\/00005792-198903000-00001"},{"key":"2019111702200505300_R35","doi-asserted-by":"crossref","unstructured":"Hendrick AM. Auto-immune haemolytic anaemia\u2014a high-risk disorder for thromboembolism? Hematology. 2003;8:53\u201356.","DOI":"10.1080\/1024533021000059474"},{"key":"2019111702200505300_R36","unstructured":"Sallah S, Wan JY, Hanrahan LR. Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia. Clin Cancer Res. 2001;7:791\u2013794."},{"key":"2019111702200505300_R37","doi-asserted-by":"crossref","unstructured":"Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 1993;44:237\u2013242.","DOI":"10.1002\/ajh.2830440404"},{"key":"2019111702200505300_R38","doi-asserted-by":"crossref","unstructured":"Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol. 1990;84:122\u2013129.","DOI":"10.1159\/000205048"},{"key":"2019111702200505300_R39","doi-asserted-by":"crossref","unstructured":"Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol. 1993;83:343\u2013345.","DOI":"10.1111\/j.1365-2141.1993.tb08293.x"},{"key":"2019111702200505300_R40","doi-asserted-by":"crossref","unstructured":"Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002;117:712\u2013715.","DOI":"10.1046\/j.1365-2141.2002.03430.x"},{"key":"2019111702200505300_R41","doi-asserted-by":"crossref","unstructured":"Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995\u20133997.","DOI":"10.1182\/blood.V97.12.3995"},{"key":"2019111702200505300_R42","doi-asserted-by":"crossref","unstructured":"Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358:1511\u20131513.","DOI":"10.1016\/S0140-6736(01)06573-4"},{"key":"2019111702200505300_R43","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003;78:1340\u20131346.","DOI":"10.4065\/78.11.1340"},{"key":"2019111702200505300_R44","unstructured":"Trape G, Fianchi L, Lai M, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica. 2003;88:223\u2013225."},{"key":"2019111702200505300_R45","doi-asserted-by":"crossref","unstructured":"Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol. 2004;77:303\u2013310.","DOI":"10.1002\/ajh.20180"},{"key":"2019111702200505300_R46","doi-asserted-by":"crossref","unstructured":"Ramanathan S, Koutts J, Hertzberg MS. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Hematol. 2005;78:123\u2013126.","DOI":"10.1002\/ajh.20220"},{"key":"2019111702200505300_R47","unstructured":"Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. 2002;87:189\u2013195."},{"key":"2019111702200505300_R48","doi-asserted-by":"crossref","unstructured":"Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002;16:2092\u20132095.","DOI":"10.1038\/sj.leu.2402676"},{"key":"2019111702200505300_R49","doi-asserted-by":"crossref","unstructured":"Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891\u2013898.","DOI":"10.1046\/j.1365-2141.2001.03039.x"},{"key":"2019111702200505300_R50","doi-asserted-by":"crossref","unstructured":"Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol. 2004;72:79\u201388.","DOI":"10.1046\/j.0902-4441.2003.00196.x"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/13\/1091448\/013_018ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/13\/1091448\/013_018ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T02:20:24Z","timestamp":1573957224000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/13\/19734\/Immune-Hemolytic-AnemiaSelected-Topics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.13","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}